blood test early Articles
-
Case Study B - Liquid Biopsy
X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood. The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially ...
By X-Zell Inc.
-
Universal Diagnostics - Case Study
Name: Paola Hurtado Job Title: Laboratory Director Company: Universal Diagnostics, Spain Infinity supplies LC-MS used in early detection Universal Diagnostics is a biomedicine start-up focused on the development of cutting-edge technologies in metabolomics, genetics and bioinformatics, with the mission to develop a blood test for early detection. Based on proprietary technologies and ...
-
Diabetomics Lumella - New Point-of-Care Blood Test Kit for Early Detection of Preeclampsia
Abstract Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints. Anticitrullinated protein autoantibodies are detected by the CCP test in early disease and predict the development of erosive disease as well as extraarticular manifestations. We recently reported that many RA patients have anti-citrullinated albumin (ACA) ...
-
Universal Diagnostics Initiates Observational Study in the US to Evaluate Cell Free DNA Blood Test for Adenomas and Colorectal Cancer
SEVILLE, Spain--(BUSINESS WIRE)--Universal Diagnostics (UDX), an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced today that it has started a prospective, multi-center observational study in the US for its investigational advanced adenoma (precursor lesions) and colorectal cancer (CRC) detection blood test. UDX is performing ...
-
Nano-Flow Cytometry: A Revolutionary Tool for Biomedical Research
Nano-flow cytometry is a revolutionary technology that has the potential to transform early disease detection and diagnosis. Nano-flow cytometers are able to detect and analyze individual nanoparticles, including extracellular vesicles and viruses, with high sensitivity and accuracy. This makes them ideal for detecting diseases at their earliest stages, when they are most treatable. How does ...
-
Our innovative technology becomes available for patients
Following a successful fundraising in Q4 2016, METAFORA achieves an important milestone by announcing, in partnership with CERBA Healthcare, the availability of the METAglut1 blood test to diagnose the GLUT1 deficiency syndrome (GLUT1 DS). Through METAglut1, our disruptive technology becomes available, for the first time, to patients. De Vivo’s disease (the other name of GLUT1 DS) is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you